This is a multi-center, open label, Phase 1b study of NXP900 in combination with lorlatinib in subjects with advanced, ALK-positive non-small cell lung cancer …

ALK PositiveALK Positive Non-small Cell Lung CancerNSCLC+1 more

~Estimated

~$10 – $8,750

Nuvectis Pharma, Inc.NCT07784959

The Gut Microbiome and Immune Checkpoint Inhibitor Therapy in Solid Tumors

The microbiome has the potential to serve as a robust biomarker of clinical response to immunotherapy. Additionally, microbial manipulation, through diet, exer…

Non-Small-Cell Lung CarcinomaMalignant MelanomaRenal Cell Carcinoma+1 more

~Estimated

~$10 – $1,125

VastBiomeNCT05037825